Gerrit L. J. Onderwater
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Gerrit L. J. Onderwater has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Gisela Marie Terwindt
Leiden University Medical Center
5 shared publications Michel D. Ferrari
Department of Neurology Leiden University Medical Center Leiden The Netherlands
5 shared publicationsGisela M. Terwindt
Department of Neurology Leiden University Medical Center Leiden The Netherlands
3 shared publications- Robin M. van Dongen
Leiden University Medical Center
3 shared publications Ronald Zielman
Department of Neurology Leiden University Medical Center Leiden The Netherlands
3 shared publicationsAmy C. Harms
Division of Analytical Biosciences Leiden Academic Center for Drug Research Leiden the Netherlands
2 shared publications
Latest Publications
- Open Access
- 11 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9899
Correlation of Amine Concentrations in Blood and Cerebrospinal Fluid in Healthy Volunteers and Migraineurs
Many central nervous system disorders (CNS), including chronic pain and migraine, involve metabolic changes in the brain. These changes are best detected and monitored in cerebrospinal fluid (CSF), which requires lumbar puncture. Blood-based measurements may offer an alternative, if they reflect CSF changes. To assess this, we measured and correlated the concentrations of 39 amino acids, biogenic amines, and other amines in blood and CSF of 95 healthy volunteers and, in addition, correlated the ratios of 741 amines. Amines were measured using a validated UPLC-MS platform. In healthy volunteers, only 4/39 (10.3%) analyzed amine metabolite concentrations had a correlation coefficient ≥ 0.70. Correlations of metabolite ratios were significantly better for 308/741 (41.5%) combinations. Specifically, ratios of amino acids showed high correlations. In addition, amines were investigated in 197 participants with migraine. Six amine metabolite ratios were different in migraineurs versus healthy volunteers. Most blood amine concentrations do not reflect those in CSF, but many of the ratios did correlate between CSF and plasma, showing diagnostic potential. This study improves our understanding of blood-CSF relationships, and our data suggest that ratios of amines may be of relevance to CNS disorders, as we showed for migraine.
- 11 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9899
Open AccessCorrelation of Amine Concentrations in Blood and Cerebrospinal Fluid in Healthy Volunteers and Migraineurs
Many central nervous system disorders (CNS), including chronic pain and migraine, involve metabolic changes in the brain. These changes are best detected and monitored in cerebrospinal fluid (CSF), which requires lumbar puncture. Blood-based measurements may offer an alternative, if they reflect CSF changes. To assess this, we measured and correlated the concentrations of 39 amino acids, biogenic amines, and other amines in blood and CSF of 95 healthy volunteers and, in addition, correlated the ratios of 741 amines. Amines were measured using a validated UPLC-MS platform. In healthy volunteers, only 4/39 (10.3%) analyzed amine metabolite concentrations had a correlation coefficient ≥ 0.70. Correlations of metabolite ratios were significantly better for 308/741 (41.5%) combinations. Specifically, ratios of amino acids showed high correlations. In addition, amines were investigated in 197 participants with migraine. Six amine metabolite ratios were different in migraineurs versus healthy volunteers. Most blood amine concentrations do not reflect those in CSF, but many of the ratios did correlate between CSF and plasma, showing diagnostic potential. This study improves our understanding of blood-CSF relationships, and our data suggest that ratios of amines may be of relevance to CNS disorders, as we showed for migraine.
- Open Access
- 30 January 2023
- Published by Wiley in Annals of Neurology
- Vol. 93 (4) , 715-728
Cerebrospinal Fluid and Plasma Amine Profiles in Interictal Migraine
Objective: Impaired amine metabolism has been associated with the etiology of migraine, that is, why patients continue to get migraine attacks. However, evidence from cerebrospinal fluid (CSF) is lacking. Here, we evaluated individual amine levels, global amine profiles, and amine pathways in CSF and plasma of interictal migraine patients and healthy controls.Methods: CSF and plasma were sampled between 8:30 AM and 1:00 PM, randomly and interchangeably over the time span to avoid any diurnal and seasonal influences, from healthy volunteers and interictal migraine patients, matched for age, sex, and sampling time. The study was approved by the local medical ethics committee. Individual amines (n = 31), global amine profiles, and specific amine pathways were analyzed using a validated ultraperformance liquid chromatography mass spectrometry platform. Results: We analyzed n = 99 participants with migraine with aura, n = 98 with migraine without aura, and n = 96 healthy volunteers. Univariate analysis with Bonferroni correction indicated that CSF L-arginine was reduced in migraine with aura (10.4%, p < 0.001) and without aura (5.0%, p = 0.03). False discovery rate-corrected CSF L-phenylalanine was also lower in migraine with aura (6.9%, p = 0.011) and without aura (8.1%, p = 0.001), p = 0.088 after Bonferroni correction. Multivariate analysis revealed that CSF global amine profiles were similar for both types of migraine (p = 0.64), but distinct from controls (p = 0.009). Global profile analyses were similar in plasma. The strongest associated path-ways with migraine were related to L-arginine metabolism. Interpretation: L-Arginine was decreased in the CSF (but not in plasma) of interictal patients with migraine with or without aura, and associated pathways were altered. This suggests that dysfunction of nitric oxide signaling is involved in susceptibility to getting migraine attacks.
- 30 January 2023
- Published by Wiley in Annals of Neurology
- Vol. 93 (4) , 715-728
Open AccessCerebrospinal Fluid and Plasma Amine Profiles in Interictal Migraine
Objective: Impaired amine metabolism has been associated with the etiology of migraine, that is, why patients continue to get migraine attacks. However, evidence from cerebrospinal fluid (CSF) is lacking. Here, we evaluated individual amine levels, global amine profiles, and amine pathways in CSF and plasma of interictal migraine patients and healthy controls.Methods: CSF and plasma were sampled between 8:30 AM and 1:00 PM, randomly and interchangeably over the time span to avoid any diurnal and seasonal influences, from healthy volunteers and interictal migraine patients, matched for age, sex, and sampling time. The study was approved by the local medical ethics committee. Individual amines (n = 31), global amine profiles, and specific amine pathways were analyzed using a validated ultraperformance liquid chromatography mass spectrometry platform. Results: We analyzed n = 99 participants with migraine with aura, n = 98 with migraine without aura, and n = 96 healthy volunteers. Univariate analysis with Bonferroni correction indicated that CSF L-arginine was reduced in migraine with aura (10.4%, p < 0.001) and without aura (5.0%, p = 0.03). False discovery rate-corrected CSF L-phenylalanine was also lower in migraine with aura (6.9%, p = 0.011) and without aura (8.1%, p = 0.001), p = 0.088 after Bonferroni correction. Multivariate analysis revealed that CSF global amine profiles were similar for both types of migraine (p = 0.64), but distinct from controls (p = 0.009). Global profile analyses were similar in plasma. The strongest associated path-ways with migraine were related to L-arginine metabolism. Interpretation: L-Arginine was decreased in the CSF (but not in plasma) of interictal patients with migraine with or without aura, and associated pathways were altered. This suggests that dysfunction of nitric oxide signaling is involved in susceptibility to getting migraine attacks.
- Open Access
- 12 May 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (8) , 2631-2638
Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without
Background and purpose: This study was undertaken to investigate migraine prevalence in persons with hallucinogen persisting perception disorder (HPPD) presenting as visual snow syndrome (VSS).Methods: Persons with visual snow as a persisting symptom after illicit drug use (HPPD) were recruited via a Dutch consulting clinic for recreational drug use. A structured interview on (visual) perceptual symptomatology, details of drugs use, and medical and headache history was taken. As a control group, persons with visual snow who had never used illicit drugs prior to onset were included. The primary outcome was lifetime prevalence of migraine. Symptom severity was evaluated by the Visual Snow Handicap Inventory (VHI), a 25‐item questionnaire.Results: None of the 24 HPPD participants had migraine, whereas 20 of 37 (54.1%) controls had migraine (p < 0.001). VHI scores did not differ significantly between the two groups; in both groups, the median score was 38 of 100. In most HPPD cases (17/24, 70.9%), visual snow had started after intake of ecstasy; other psychedelic drugs reported included cannabis, psilocybin mushrooms, amphetamine, 4‐fluoroamphetamine, 3‐methylmethcathinone, 4‐Bromo‐2,5‐dimethoxypenethylamine, and nitrous oxide.Conclusions: Whereas none of the HPPD participants had migraine, more than half of the visual snow controls without prior use of illicit drugs had migraine. This suggests that at least partly different pathophysiological factors play a role in these disorders. Users of ecstasy and other hallucinogens should be warned of the risk of visual snow. Further studies are needed to enhance understanding of the underlying neurobiology of HPPD and VSS to enable better management of these conditions.
- 12 May 2021
- Published by Wiley in European Journal of Neurology
- Vol. 28 (8) , 2631-2638
Open AccessMigraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without
Background and purpose: This study was undertaken to investigate migraine prevalence in persons with hallucinogen persisting perception disorder (HPPD) presenting as visual snow syndrome (VSS).Methods: Persons with visual snow as a persisting symptom after illicit drug use (HPPD) were recruited via a Dutch consulting clinic for recreational drug use. A structured interview on (visual) perceptual symptomatology, details of drugs use, and medical and headache history was taken. As a control group, persons with visual snow who had never used illicit drugs prior to onset were included. The primary outcome was lifetime prevalence of migraine. Symptom severity was evaluated by the Visual Snow Handicap Inventory (VHI), a 25‐item questionnaire.Results: None of the 24 HPPD participants had migraine, whereas 20 of 37 (54.1%) controls had migraine (p < 0.001). VHI scores did not differ significantly between the two groups; in both groups, the median score was 38 of 100. In most HPPD cases (17/24, 70.9%), visual snow had started after intake of ecstasy; other psychedelic drugs reported included cannabis, psilocybin mushrooms, amphetamine, 4‐fluoroamphetamine, 3‐methylmethcathinone, 4‐Bromo‐2,5‐dimethoxypenethylamine, and nitrous oxide.Conclusions: Whereas none of the HPPD participants had migraine, more than half of the visual snow controls without prior use of illicit drugs had migraine. This suggests that at least partly different pathophysiological factors play a role in these disorders. Users of ecstasy and other hallucinogens should be warned of the risk of visual snow. Further studies are needed to enhance understanding of the underlying neurobiology of HPPD and VSS to enable better management of these conditions.
- Open Access
- 23 July 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 93 (4) , e398-e403
Treatment effects and comorbid diseases in 58 patients with visual snow
Objective To evaluate pharmacologic treatment options for visual snow and to report prevalence of comorbid diseases. Methods Medical charts of patients with a diagnosis of visual snow at the neurology outpatient clinic were reviewed on prescribed medication, and comorbid migraine, tinnitus, and psychiatric conditions including depression and anxiety. Results From 2007 to 2018, 58 patients were diagnosed with visual snow. Comorbid migraine was present in 51.7% of patients, lifetime depression in 41.4%, and lifetime anxiety in 44.8%. Lamotrigine was prescribed most frequently (26/58) and resulted in partial remission of symptoms in 5/26 (19.2%). No patients reported complete remission. Adverse events occurred in 13/26 (50.0%) patients. None of the other prescribed drugs (valproate [n = 7], topiramate [n = 4], acetazolamide [n = 2], flunarizine [n = 1]) led to improvement except for topiramate in one patient, who discontinued, however, because of adverse events. Conclusions Of medication prescribed (lamotrigine, valproate, acetazolamide, flunarizine), only lamotrigine afforded some improvement in a small minority of patients. Migraine, depression, anxiety, and tinnitus were common comorbid diseases. Classification of evidence This study provides Class IV evidence that for some patients with visual snow, lamotrigine resulted in partial remission of symptoms.
- 23 July 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 93 (4) , e398-e403
Open AccessTreatment effects and comorbid diseases in 58 patients with visual snow
Objective To evaluate pharmacologic treatment options for visual snow and to report prevalence of comorbid diseases. Methods Medical charts of patients with a diagnosis of visual snow at the neurology outpatient clinic were reviewed on prescribed medication, and comorbid migraine, tinnitus, and psychiatric conditions including depression and anxiety. Results From 2007 to 2018, 58 patients were diagnosed with visual snow. Comorbid migraine was present in 51.7% of patients, lifetime depression in 41.4%, and lifetime anxiety in 44.8%. Lamotrigine was prescribed most frequently (26/58) and resulted in partial remission of symptoms in 5/26 (19.2%). No patients reported complete remission. Adverse events occurred in 13/26 (50.0%) patients. None of the other prescribed drugs (valproate [n = 7], topiramate [n = 4], acetazolamide [n = 2], flunarizine [n = 1]) led to improvement except for topiramate in one patient, who discontinued, however, because of adverse events. Conclusions Of medication prescribed (lamotrigine, valproate, acetazolamide, flunarizine), only lamotrigine afforded some improvement in a small minority of patients. Migraine, depression, anxiety, and tinnitus were common comorbid diseases. Classification of evidence This study provides Class IV evidence that for some patients with visual snow, lamotrigine resulted in partial remission of symptoms.
- Open Access
- 16 April 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (16) , e1899-e1911
Large-scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine
Objective To identify a plasma metabolomic biomarker signature for migraine. Methods Plasma samples from 8 Dutch cohorts (n = 10,153: 2,800 migraine patients and 7,353 controls) were profiled on a 1H-NMR-based metabolomics platform, to quantify 146 individual metabolites (e.g., lipids, fatty acids, and lipoproteins) and 79 metabolite ratios. Metabolite measures associated with migraine were obtained after single-metabolite logistic regression combined with a random-effects meta-analysis performed in a nonstratified and sex-stratified manner. Next, a global test analysis was performed to identify sets of related metabolites associated with migraine. The Holm procedure was applied to control the family-wise error rate at 5% in single-metabolite and global test analyses. Results Decreases in the level of apolipoprotein A1 (β −0.10; 95% confidence interval [CI] −0.16, −0.05; adjusted p = 0.029) and free cholesterol to total lipid ratio present in small high-density lipoprotein subspecies (HDL) (β −0.10; 95% CI −0.15, −0.05; adjusted p = 0.029) were associated with migraine status. In addition, only in male participants, a decreased level of omega-3 fatty acids (β −0.24; 95% CI −0.36, −0.12; adjusted p = 0.033) was associated with migraine. Global test analysis further supported that HDL traits (but not other lipoproteins) were associated with migraine status. Conclusions Metabolic profiling of plasma yielded alterations in HDL metabolism in migraine patients and decreased omega-3 fatty acids only in male migraineurs.
- 16 April 2019
- Published by Wolters Kluwer Health in Neurology
- Vol. 92 (16) , e1899-e1911
Open AccessLarge-scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine
Objective To identify a plasma metabolomic biomarker signature for migraine. Methods Plasma samples from 8 Dutch cohorts (n = 10,153: 2,800 migraine patients and 7,353 controls) were profiled on a 1H-NMR-based metabolomics platform, to quantify 146 individual metabolites (e.g., lipids, fatty acids, and lipoproteins) and 79 metabolite ratios. Metabolite measures associated with migraine were obtained after single-metabolite logistic regression combined with a random-effects meta-analysis performed in a nonstratified and sex-stratified manner. Next, a global test analysis was performed to identify sets of related metabolites associated with migraine. The Holm procedure was applied to control the family-wise error rate at 5% in single-metabolite and global test analyses. Results Decreases in the level of apolipoprotein A1 (β −0.10; 95% confidence interval [CI] −0.16, −0.05; adjusted p = 0.029) and free cholesterol to total lipid ratio present in small high-density lipoprotein subspecies (HDL) (β −0.10; 95% CI −0.15, −0.05; adjusted p = 0.029) were associated with migraine status. In addition, only in male participants, a decreased level of omega-3 fatty acids (β −0.24; 95% CI −0.36, −0.12; adjusted p = 0.033) was associated with migraine. Global test analysis further supported that HDL traits (but not other lipoproteins) were associated with migraine status. Conclusions Metabolic profiling of plasma yielded alterations in HDL metabolism in migraine patients and decreased omega-3 fatty acids only in male migraineurs.
- 18 December 2018
- Published by Wiley in European Journal of Neurology
- Vol. 26 (4) , 588-595
Alcoholic beverages as trigger factor and the effect on alcohol consumption behavior in patients with migraine
Background and purpose: Alcoholic beverages are frequently reported migraine triggers. We aimed to assess self‐reported alcohol consumption as a migraine attack trigger and to investigate the effect on alcohol consumption behavior in a large migraine cohort.Methods: We conducted a cross‐sectional, web‐based, questionnaire study among 2197 patients with migraine from the well‐defined Leiden University MIgraine Neuro‐Analysis (LUMINA) study population. We assessed alcoholic beverage consumption and self‐reported trigger potential, reasons behind alcohol abstinence and time between alcohol consumption and migraine attack onset.Results: Alcoholic beverages were reported as a trigger by 35.6% of participants with migraine. In addition, over 25% of patients with migraine who had stopped consuming or never consumed alcoholic beverages did so because of presumed trigger effects. Wine, especially red wine (77.8% of participants), was recognized as the most common trigger among the alcoholic beverages. However, red wine consistently led to an attack in only 8.8% of participants. Time of onset was rapid (<3 h) in one‐third of patients and almost 90% had an onset <10 h independent of beverage type.Conclusions: Alcoholic beverages, especially red wine, are recognized as a migraine trigger factor by patients with migraine and have a substantial effect on alcohol consumption behavior. Rapid onset of provoked migraine attacks in contrast to what is known about hangover headache might point to a different mechanism. The low consistency of provocation suggests that alcoholic beverages acting as a singular trigger is insufficient and may depend on a fluctuating trigger threshold.
- 18 December 2018
- Published by Wiley in European Journal of Neurology
- Vol. 26 (4) , 588-595
Alcoholic beverages as trigger factor and the effect on alcohol consumption behavior in patients with migraine
Background and purpose: Alcoholic beverages are frequently reported migraine triggers. We aimed to assess self‐reported alcohol consumption as a migraine attack trigger and to investigate the effect on alcohol consumption behavior in a large migraine cohort.Methods: We conducted a cross‐sectional, web‐based, questionnaire study among 2197 patients with migraine from the well‐defined Leiden University MIgraine Neuro‐Analysis (LUMINA) study population. We assessed alcoholic beverage consumption and self‐reported trigger potential, reasons behind alcohol abstinence and time between alcohol consumption and migraine attack onset.Results: Alcoholic beverages were reported as a trigger by 35.6% of participants with migraine. In addition, over 25% of patients with migraine who had stopped consuming or never consumed alcoholic beverages did so because of presumed trigger effects. Wine, especially red wine (77.8% of participants), was recognized as the most common trigger among the alcoholic beverages. However, red wine consistently led to an attack in only 8.8% of participants. Time of onset was rapid (<3 h) in one‐third of patients and almost 90% had an onset <10 h independent of beverage type.Conclusions: Alcoholic beverages, especially red wine, are recognized as a migraine trigger factor by patients with migraine and have a substantial effect on alcohol consumption behavior. Rapid onset of provoked migraine attacks in contrast to what is known about hangover headache might point to a different mechanism. The low consistency of provocation suggests that alcoholic beverages acting as a singular trigger is insufficient and may depend on a fluctuating trigger threshold.
- Open Access
- 14 June 2017
- Published by Oxford University Press (OUP) in Brain
- Vol. 140 (7) , 1859-1871
Cortical glutamate in migraine
Cortical hyperexcitability due to enhanced glutamatergic activity has been implicated in migraine pathophysiology but direct evidence is lacking. Here we assessed glutamate levels and intracellular mobility of glutamate in the visual cortex of migraineurs in-between attacks. We included 50 migraineurs (23 with aura and 27 without aura) and 24 age- and gender-matched non-headache controls. We used proton magnetic resonance spectroscopy (1H-MRS) and diffusion weighted spectroscopy at 7 T with a single volume of interest (2 × 2 × 3 cm) located in the primary and secondary visual cortex. For 1H-MRS we used a semi-LASER sequence with water referencing for absolute quantification. For diffusion weighted spectroscopy we used an adapted PRESS sequence with gradients applied in three directions and two different gradient amplitudes. Between-group differences were evaluated using analysis of covariance with the grey matter fraction in the volume of interest as covariate and post hoc comparisons with Bonferroni correction. Glutamate concentrations differed between groups (P = 0.047) and were higher in migraineurs without aura (mean ± standard deviation: 7.02 ± 0.50 mM) compared to controls (mean ± standard deviation: 6.40 ± 0.78 mM, P = 0.042). The apparent diffusion coefficient of glutamate was similar among groups (P = 0.129) suggesting similar inter- and intracellular mobility of glutamate in all three study groups. No differences were observed for concentrations and diffusion constants of other metabolites. The present study suggests that interictal glutamate levels are increased in the visual cortex of migraineurs without aura, supporting the hypothesis of cortical hyperexcitability in migraine.
- 14 June 2017
- Published by Oxford University Press (OUP) in Brain
- Vol. 140 (7) , 1859-1871
Open AccessCortical glutamate in migraine
Cortical hyperexcitability due to enhanced glutamatergic activity has been implicated in migraine pathophysiology but direct evidence is lacking. Here we assessed glutamate levels and intracellular mobility of glutamate in the visual cortex of migraineurs in-between attacks. We included 50 migraineurs (23 with aura and 27 without aura) and 24 age- and gender-matched non-headache controls. We used proton magnetic resonance spectroscopy (1H-MRS) and diffusion weighted spectroscopy at 7 T with a single volume of interest (2 × 2 × 3 cm) located in the primary and secondary visual cortex. For 1H-MRS we used a semi-LASER sequence with water referencing for absolute quantification. For diffusion weighted spectroscopy we used an adapted PRESS sequence with gradients applied in three directions and two different gradient amplitudes. Between-group differences were evaluated using analysis of covariance with the grey matter fraction in the volume of interest as covariate and post hoc comparisons with Bonferroni correction. Glutamate concentrations differed between groups (P = 0.047) and were higher in migraineurs without aura (mean ± standard deviation: 7.02 ± 0.50 mM) compared to controls (mean ± standard deviation: 6.40 ± 0.78 mM, P = 0.042). The apparent diffusion coefficient of glutamate was similar among groups (P = 0.129) suggesting similar inter- and intracellular mobility of glutamate in all three study groups. No differences were observed for concentrations and diffusion constants of other metabolites. The present study suggests that interictal glutamate levels are increased in the visual cortex of migraineurs without aura, supporting the hypothesis of cortical hyperexcitability in migraine.
- Open Access
- 1 March 2017
- Published by Elsevier in Journal of Lipid Research
- Vol. 58 (3) , 615-624
Quantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS
- 1 March 2017
- Published by Elsevier in Journal of Lipid Research
- Vol. 58 (3) , 615-624
Open AccessQuantitative profiling of endocannabinoids and related N-acylethanolamines in human CSF using nano LC-MS/MS